eGenesis pushes to bring pig organ transplants to humans with $100M series B

eGenesis is aiming to be the first to transplant genetically engineered pig organs into humans with its $100 million series B round, which will allow the Cambridge, Mass.-based company to advance multiple programs in parallel.

Fresenius Medical Care Ventures led the untranched round. New investors Leaps by Bayer -- which contributed $50 million -- and Wellington Partners also participated, as did existing investors including Arch Venture Partners, Biomatics Capital, Alta Partners and Khosla Ventures...